Literature DB >> 28903137

Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.

Dhruv S Kazi1, Christine Y Lu2,3, Grace A Lin4, Colette DeJong4, R Adams Dudley4, Randi Chen5, Chien-Wen Tseng6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28903137      PMCID： PMC5815006          DOI： 10.1001/jamacardio.2017.3051

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  4 in total

1.  Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.

Authors:  Kevin A Schulman; Suresh Balu; Shelby D Reed
Journal:  N Engl J Med       Date:  2015-10-07       Impact factor: 91.245

2.  Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Authors:  Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo
Journal:  JAMA       Date:  2016-08-16       Impact factor: 56.272

3.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

4.  Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes.

Authors:  Jessica Williams; William N Steers; Susan L Ettner; Carol M Mangione; Obidiugwu K Duru
Journal:  Med Care       Date:  2013-02       Impact factor: 2.983
  4 in total
  5 in total

1.  Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.

Authors:  Dhruv S Kazi; Brandon K Bellows; Suzanne J Baron; Changyu Shen; David J Cohen; John A Spertus; Robert W Yeh; Suzanne V Arnold; Brett W Sperry; Mathew S Maurer; Sanjiv J Shah
Journal:  Circulation       Date:  2020-02-12       Impact factor: 29.690

2.  PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.

Authors:  Alanna M Chamberlain; Yan Gong; Kathryn McAuliffe Shaw; Jiang Bian; Wen-Liang Song; MacRae F Linton; Vivian Fonseca; Eboni Price-Haywood; Emily Guhl; Jordan B King; Rashmee U Shah; Jon Puro; Elizabeth Shenkman; Pamala A Pawloski; Karen L Margolis; Adrian F Hernandez; Rhonda M Cooper-DeHoff
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

Review 3.  The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.

Authors:  Merilyn S Varghese; Chia-Liang Liu; Dhruv S Kazi
Journal:  Curr Cardiol Rep       Date:  2021-10-01       Impact factor: 2.931

4.  Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.

Authors:  Nicolas Isaza; Paola Calvachi; Inbar Raber; Chia-Liang Liu; Brandon K Bellows; Inmaculada Hernandez; Changyu Shen; Michael C Gavin; A Reshad Garan; Dhruv S Kazi
Journal:  JAMA Netw Open       Date:  2021-07-01

5.  Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.

Authors:  Jing Luo; Robert Feldman; Scott D Rothenberger; Inmaculada Hernandez; Walid F Gellad
Journal:  JAMA Netw Open       Date:  2020-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.